UNSPSC 51384503: Benoxaprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H12ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17SZX404IM, chemically known as 5-benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl, (+-)- but generally known as benoxaprofen, which bears US NIH Compound Identifier 39941. Benoxaprofen most often comes in base and glucuronide forms. European Medicines Agency schedules Benoxaprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05725MIG.

UNSPSC 51384503 Benoxaprofen, a Commodity code, shows little relevant recent activity. The code nominally covers a specific nonsteroidal anti-inflammatory drug, but the three most recent state and local opportunities posted under or near this code do not align with benoxaprofen procurement. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems — opioid antagonists and harm-reduction devices unrelated to benoxaprofen. The Texas Health and Human Services Commission posted an RFI in April 2026 on a Therapeutic Pharmacy Initiative for direct-to-manufacturer prescription programs, a policy exploration with no specific drug named. Minnesota's MMCAP cooperative purchasing vehicle issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across a broad spectrum, with no benoxaprofen specified in the scope.

The mismatch suggests that benoxaprofen, a drug rarely prescribed in modern clinical practice due to safety concerns and withdrawal from many markets, does not drive current state and local procurement activity. Recent opportunities in pharmaceutical procurement under or adjacent to this code reflect broader categories — naloxone kits tied to opioid response, cooperative purchasing of generic pharmaceuticals at scale, and strategic initiatives to reshape pharmacy benefit programs. State and local buyers are not pursuing benoxaprofen as a named line item. Business development professionals evaluating this code should note the absence of benoxaprofen-specific demand and assess whether repositioning toward broader generic pharmaceutical supply chains or harm-reduction product procurement aligns with their capability.